Evidence map›Paper›PMID 41994903›Full record

Trial reportDiabetes, obesity & metabolism2026

Semaglutide Treatment in Young Adults Living With Type 2 Diabetes: A Post Hoc Analysis From the SUSTAIN and PIONEER Clinical Trials.

Francesco Zaccardi, Vanita R Aroda, Ecenur Guder Arslan, Lars Bardtrum, Jonathan Goldney, Erik Ising, Prachi Priyadarshini, Tommy Slater, Melanie J Davies

Abstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Diabetes, obesity & metabolism, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Francesco ZaccardiLeicester Real World Evidence Unit, Diabetes Research Centre, University of Leicester, Leicester, UK.
Vanita R ArodaDivision of Endocrinology, Diabetes and Hypertension, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.ORCID https://orcid.org/0000-0002-7706-4585
Ecenur Guder ArslanNovo Nordisk A/S, Søborg, Denmark.
Lars BardtrumNovo Nordisk A/S, Søborg, Denmark.
Jonathan GoldneyDiabetes Research Centre, University of Leicester, Leicester, UK.ORCID https://orcid.org/0000-0001-8553-8296
Erik IsingNovo Nordisk A/S, Søborg, Denmark.
Prachi PriyadarshiniNovo Nordisk GBS, Bengaluru, India.
Tommy SlaterDiabetes Research Centre, University of Leicester, Leicester, UK.
Melanie J DaviesDiabetes Research Centre, University of Leicester, Leicester, UK.

Funding

National Institute for Health and Care Research (NIHR) NIHR201165NIHR Leicester Biomedical Research CentreNovo NordiskWellcome Trust Leicestershire Healthcare Inequalities Improvement Doctoral Training Programme 223512/Z/21/Z
6 · The paper itself

Abstract

aimsYoung adults (aged ≤ 40 years) are underrepresented in clinical trials that investigate interventions for those living with Type 2 diabetes (T2D). This study evaluated the efficacy of semaglutide treatment in young adults with T2D by examining the effects on HbA MATERIALS AND

methodsThis post hoc analysis of the SUSTAIN (once-weekly subcutaneous administration) and PIONEER (once-daily oral administration) programmes assessed the efficacy of semaglutide treatment in different age subgroups by comparing change in HbA

resultsFindings indicate a reduction in HbA

conclusionsSemaglutide shows notable and consistent efficacy in reducing HbA

Indexed as

Diabetes Mellitus, Type 2Glucagon-Like PeptidesHypoglycemic AgentsAdministration, OralAdultAge FactorsBlood GlucoseBody WeightFemaleGlycated HemoglobinHumansInjections, SubcutaneousMaleMiddle AgedSemaglutideTreatment OutcomeBlood GlucoseGlucagon-Like PeptidesGlycated Hemoglobinhemoglobin A1c protein, humanHypoglycemic AgentsSemaglutidecohort studyGLP‐1glycaemic controlmeta‐analysissemaglutidetype 2 diabetes

Identifiers

PMID41994903
PMCPMC13243996

What Socratic holds

Texttitle and abstract
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.